Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (2C-B)

This RCT (n=24) does a direct comparison, the first one in a double-blind trial, of MDMA, psilocybin, and 2C-B (a novel psychedelic with MDMA & psilocybin-like effects). Next to a placebo, the dosages of MDMA (125mg) and psilocybin (25mg) are high, whilst that of 2C-B will be a variety of doses (10, 20, 30mg). All participants will receive all compounds and a placebo (cross-over study design).

Topic Healthy Subjects
Compound MDMA 2C-X Psilocybin
Country Switzerland
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.